"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2.B-Cell Chronic Lymphocytic Leukemia - Overview
3.Executive Summary
4. B-Cell Chronic Lymphocytic Leukemia: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. B-Cell Chronic Lymphocytic Leukemia: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. ALXN6000 – Alexion
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. PCI-32765– Pharmacyclics LLC.
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. BGB-3111 – BeiGene
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. B-Cell Chronic Lymphocytic Leukemia: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. B-Cell Chronic Lymphocytic Leukemia: Additional Key Insights
7.1. Epidemiology Overview: B-Cell Chronic Lymphocytic Leukemia
7.2. Prognosis and Survival: B-Cell Chronic Lymphocytic Leukemia
8. B-Cell Chronic Lymphocytic Leukemia: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.